These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 7622903)

  • 1. Equal IgG antibody response to pneumococcal vaccination in all stages of human immunodeficiency virus disease.
    Vandenbruaene M; Colebunders R; Mascart-Lemone F; Haerden Y; Van Hove D; Peeters M; Goeman J; Van Royen P; Avonts D
    J Infect Dis; 1995 Aug; 172(2):551-3. PubMed ID: 7622903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time course of antibody response to tetanus toxoid and pneumococcal capsular polysaccharides in patients infected with HIV.
    Talesnik E; Vial PA; Labarca J; Méndez C; Soza X
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Dec; 19(5):471-7. PubMed ID: 9859960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential effect of human immunodeficiency virus infection on the IgA and IgG antibody responses to pneumococcal vaccine.
    Mascart-Lemone F; Gérard M; Libin M; Crusiaux A; Franchioly P; Lambrechts A; Goldman M; Clumeck N
    J Infect Dis; 1995 Nov; 172(5):1253-60. PubMed ID: 7594661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response of recent human immunodeficiency virus seroconverters to the pneumococcal polysaccharide vaccine and Haemophilus influenzae type b conjugate vaccine.
    Weiss PJ; Wallace MR; Oldfield EC; O'Brien J; Janoff EN
    J Infect Dis; 1995 May; 171(5):1217-22. PubMed ID: 7751696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Reactogenicity, safety, immunogenicity and prophylactic effectiveness of polysaccharide pneumococcus vaccine during immunization of HIV-infected patients].
    Fel'dblium IV; Nikolenko VV; Vorob'eva NN; Ivanova ÉS; Shmagel' NG; Khafizov KM; Iurganova GA; Zverev SIa
    Zh Mikrobiol Epidemiol Immunobiol; 2013; (3):52-60. PubMed ID: 24000594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of human immunodeficiency virus type 1 infection on the antibody response to a glycoprotein conjugate pneumococcal vaccine: results from a randomized trial.
    Ahmed F; Steinhoff MC; Rodriguez-Barradas MC; Hamilton RG; Musher DM; Nelson KE
    J Infect Dis; 1996 Jan; 173(1):83-90. PubMed ID: 8537687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IgG antibody to pneumococcal capsular polysaccharide in human immunodeficiency virus-infected subjects: persistence of antibody in responders, revaccination in nonresponders, and relationship of immunoglobulin allotype to response.
    Rodriguez-Barradas MC; Groover JE; Lacke CE; Gump DW; Lahart CJ; Pandey JP; Musher DM
    J Infect Dis; 1996 Jun; 173(6):1347-53. PubMed ID: 8648206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody response to influenza, tetanus and pneumococcal vaccines in HIV-seropositive individuals in relation to the number of CD4+ lymphocytes.
    Kroon FP; van Dissel JT; de Jong JC; van Furth R
    AIDS; 1994 Apr; 8(4):469-76. PubMed ID: 7912086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibodies to pneumococcal capsular polysaccharides in children with human immunodeficiency virus infection given polyvalent pneumococcal vaccine.
    Arpadi SM; Back S; O'Brien J; Janoff EN
    J Pediatr; 1994 Jul; 125(1):77-9. PubMed ID: 8021792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody to capsular polysaccharides of Streptococcus pneumoniae after vaccination of human immunodeficiency virus-infected subjects with 23-valent pneumococcal vaccine.
    Rodriguez-Barradas MC; Musher DM; Lahart C; Lacke C; Groover J; Watson D; Baughn R; Cate T; Crofoot G
    J Infect Dis; 1992 Mar; 165(3):553-6. PubMed ID: 1347058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of 23-valent pneumococcal polysaccharide vaccine in children with human immunodeficiency virus undergoing highly active antiretroviral therapy.
    Tangsinmankong N; Kamchaisatian W; Day NK; Sleasman JW; Emmanuel PJ
    Ann Allergy Asthma Immunol; 2004 May; 92(5):558-64. PubMed ID: 15191025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poor antibody response after tetanus and pneumococcal vaccination in immunocompromised, HIV-infected patients.
    Opravil M; Fierz W; Matter L; Blaser J; Lüthy R
    Clin Exp Immunol; 1991 May; 84(2):185-9. PubMed ID: 2025948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to pneumococcal vaccine among asymptomatic heterosexual partners of persons with AIDS and intravenous drug users infected with human immunodeficiency virus.
    Klein RS; Selwyn PA; Maude D; Pollard C; Freeman K; Schiffman G
    J Infect Dis; 1989 Nov; 160(5):826-31. PubMed ID: 2572650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid loss of specific antibodies after pneumococcal vaccination in patients with human immunodeficiency virus-1 infection.
    Nielsen H; Kvinesdal B; Benfield TL; Lundgren JD; Konradsen HB
    Scand J Infect Dis; 1998; 30(6):597-601. PubMed ID: 10225389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination.
    Bhorat AE; Madhi SA; Laudat F; Sundaraiyer V; Gurtman A; Jansen KU; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    AIDS; 2015 Jul; 29(11):1345-54. PubMed ID: 25888646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pneumococcal capsular polysaccharide vaccine induces a repertoire shift with increased VH3 expression in peripheral B cells from human immunodeficiency virus (HIV)-uninfected but not HIV-infected persons.
    Chang Q; Abadi J; Alpert P; Pirofski L
    J Infect Dis; 2000 Apr; 181(4):1313-21. PubMed ID: 10762563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative and Qualitative Antibody Responses to Immunization With the Pneumococcal Polysaccharide Vaccine in HIV-Infected Patients After Initiation of Antiretroviral Treatment: Results From a Randomized Clinical Trial.
    Rodriguez-Barradas MC; Serpa JA; Munjal I; Mendoza D; Rueda AM; Mushtaq M; Pirofski LA
    J Infect Dis; 2015 Jun; 211(11):1703-11. PubMed ID: 25538270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Responsiveness of human immunodeficiency virus type 1-infected Kenyan women with or without prior pneumococcal disease to pneumococcal vaccine.
    Janoff EN; Fasching C; Ojoo JC; O'Brien J; Gilks CF
    J Infect Dis; 1997 Apr; 175(4):975-8. PubMed ID: 9086163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Class-specific antibody response to pneumococcal capsular polysaccharides in men infected with human immunodeficiency virus type 1.
    Janoff EN; Douglas JM; Gabriel M; Blaser MJ; Davidson AJ; Cohn DL; Judson FN
    J Infect Dis; 1988 Nov; 158(5):983-90. PubMed ID: 3183430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specificity of the antibody response to the pneumococcal polysaccharide and conjugate vaccines in human immunodeficiency virus-infected adults.
    Feikin DR; Elie CM; Goetz MB; Lennox JL; Carlone GM; Romero-Steiner S; Holder PF; O'Brien WA; Whitney CG; Butler JC; Breiman RF
    Clin Diagn Lab Immunol; 2004 Jan; 11(1):137-41. PubMed ID: 14715560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.